Metaglip and Death - a phase IV clinical study of FDA data

Summary:

Death is reported as a side effect among people who take Metaglip (glipizide; metformin hydrochloride), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Metformin, and have Pain.

The study is created by eHealthMe based on reports of 622 people who have side effects when taking Metaglip from the FDA, and is updated regularly.

What is Metaglip?

Metaglip has active ingredients of glipizide; metformin hydrochloride. It is often used in type 2 diabetes. eHealthMe is studying from 629 Metaglip users. Check the latest studies of Metaglip.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 01, 2026

622 people reported to have side effects when taking Metaglip.
Among them, 12 people (1.93%) died.

Among these 12 people:

How long have people been on Metaglip when they died? *

What is the gender of people who died when taking Metaglip? *

female: 45.45 %
male: 54.55 %

What is the age of people who died when taking Metaglip? *

What are other drugs people take besides Metaglip? *

What are other side effects people have before they died? *

Dyspnea (difficult or laboured breathing): 2 people, 16.67%
Weight Decreased: 1 person, 8.33%
Musculoskeletal Pain (pain affects the bones, muscles, ligaments, tendons, and nerves): 1 person, 8.33%
Bladder Cancer: 1 person, 8.33%
Blood Urine Present: 1 person, 8.33%
Dyskinesia (abnormality or impairment of voluntary movement): 1 person, 8.33%
Gait Disturbance: 1 person, 8.33%
Heart Attack: 1 person, 8.33%
Lung Neoplasm Malignant (cancer tumour of lung): 1 person, 8.33%
Muscle Aches (muscle pain): 1 person, 8.33%

What are the existing conditions these people have? *

Pain: 3 people, 25.00%
Constipation: 2 people, 16.67%
Diabetes: 2 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 16.67%
Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 16.67%
High Blood Cholesterol: 2 people, 16.67%
Spinal Osteoarthritis (joint cartilage loss in spine): 1 person, 8.33%
Gastric Disorder (disease of stomach): 1 person, 8.33%
Cardiac Disorder: 1 person, 8.33%
Diabetic Neuropathy (neuropathic disorders that are associated with diabetes mellitus): 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Metaglip:

Metaglip (629 reports)

Expand to all the drugs that have ingredients of glipizide; metformin hydrochloride:

Death and drugs with ingredients of glipizide; metformin hydrochloride

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Metaglip:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Death:

Death (3,107 drugs)

Browse all the conditions that are associated with Death:

Death (3,686 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on glipizide; metformin hydrochloride (the active ingredients of Metaglip) and Metaglip (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.